The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

AIDS

Volumn 18, Issue 16, 2004, Pages 2137-2144

  Noor, Mustafa A ^a   Parker, Rex A ^a   O'Mara, Edward ^a   Grasela, Dennis M ^a   Currie, Alexander ^a   Hodder, Sally L ^a   Fiedorek, Fred T ^a   Haas, David W ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Atazanavir; Diabetes; Dyslipidemia; HIV protease inhibitors; Insulin resistance; Lipodystrophy; Lopinavir ritonavir

Indexed keywords

ATAZANAVIR; GLUCOSE; GLYCOGEN; INSULIN; LIPID; LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLYCOGEN; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPODYSTROPHY; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES;

EID: 7744229686     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411050-00005     Document Type: Article

References (25)

1. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003, 37(Suppl 2): S85-S90.3.
2. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999, 21:209-216.
3. Shankar SS, Degawa-Yamauchi M, Considine RV, Steinberg HO, Dube MP Indinavir-associated endothelial dysfunction is associated with increased plasma adiponectin levels. Antiviral Ther 2003, 8:L5.
4. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-F18.
5. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men, AIDS 2004, 18:641-649.
6. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.
7. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
8. Wang S, Mulvey R, Elosua C, Flint OP, Parker RA. Association of HIV-protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and myocytes. Antiviral Ther 2003, 8:L36.
9. Bahdor G, HE G-X, Cihlar T. Comparative effects of HIV-1 protease inhibitors (PIs) on lipid accumulation and glucose uptake in human and mouse adipocytes. 43rd Meeting of the American Society for Microbiology. Chicago, September, 2003, [abstract H-1954].
10. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003, 17:339-349.
11. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, et al. Atazanavir and efavirenz, each combined with fixed-dose zidovudine and lamivudine, have similar effects on body fat distribution in antiretroviral-naïve patients: 48-week results from the metabolic substudyof BMS AI424-034. Antiviral Ther 2003, 8:L13.
12. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
13. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism. 1988, 37:287-301.
14. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003, 19:825-835.
15. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003 27(Suppl. 3):S6-S11.
16. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002, 90:11G-18G.
17. Roden M, Bernroider E. Hepatic glucose metabolism in humansits role in health and disease. Best Pract Res Clin Endocrinol Metab 2003, 17:365-383.
18. Meneilly GS, Elliott T. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. Diabetes Care 1999, 22:112-118.
19. Marsh JB. Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans. Nutr Rev 2003 61:363-375.
20. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999, 25(Suppl. 3):32-40.
21. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999, 84:3J-10J.
22. Charron MJ, Katz EB. Metabolic and therapeutic lessons from genetic manipulation of GLUT4. Mol Cell Biochem 1998, 82:143-152.
23. Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI. Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 2003, 278:48283-48291.
24. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceriderich very low density lipoprotein particles. J Biol Chem 2002, 277:34182-34190.
25. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.